Skip to main content
Premium Trial:

Request an Annual Quote

FDA Should Amend Irinotecan Label to Reflect That Not All Patients Need Accompanying Dx, Study Says

NEW YORK (GenomeWeb News) — The US Food and Drug Administration should amend the label of a commonly prescribed cancer drug to reflect that a molecular diagnostic used to predict adverse events in some patients is not required for all patients, according to the findings of a recent meta-analysis.
 
“Not everyone needs a genetic test” before taking the drug, called irinotecan, and the FDA “should modify its prescription guidelines to say so,” researchers at the University of North Carolina at Chapel Hill wrote in an article appearing in the Aug. 28 Journal of the National Cancer Institute.
 
Irinotecan, also known as Camptosar, is mainly used as a second-line treatment for colorectal cancer, the third most common form of cancer in the US. In the spring of 2005, the FDA altered the drug’s label to recommend oncologists to screen patients for a variation of UGT1A1 gene, called UGT1A1*28, which could make them more susceptible to adverse events linked to the drug. One such adverse event is neutropenia, a blood disorder that limits the body’s production of white blood cells, hobbling immunity.
 
According to GenomeWeb Daily News sister publication Pharmacogenomics Reporter, the FDA required that irinotecan’s label recommend a "reduction in the starting dose" for patients known to be homozygous for the UGT1A1*28 allele. The new label did not include specific dosing information, or suggest a specific diagnostic test for the allele.
  
But according to the UNC researchers, a meta-analysis of nine irinotecan studies showed that only patients who received a medium or high dose of the drug had greater risk of developing neutropenia if they had two copies UGT1A1*28. At lower doses, however, “the risk was the same regardless of what UGT1A1 gene the patients had,” the authors said.
 
"Many institutions saw the FDA's recommendation as authorization to test all patients before treating them with irinotecan, even though many clinicians didn't think it was always necessary since low doses of the drug weren't causing problems," Howard McLeod, senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy, said in a statement accompanying the study.
 
"Our review showed that at low doses, the drug is well tolerated and can be taken by most people," McLeod said. "Testing only becomes essential when the dosage increases and genetics become a larger factor in determining what side effects patients experience.”
 
As such, the authors recommend that the FDA “amend” irinotecan’s label to describe the association between dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.